SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03215706

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease

NCT03215706 Non-Small Cell Lung Cancer
MeSH: Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO: Neoplasm of the lung Non-small cell lung carcinoma

6 Interventions

Name: Ipilimumab

Description: Specified dose on specified day

Type: Biological

Module A

Name: Nivolumab

Description: Specified dose on specified day

Type: Biological

Module A

Name: Carboplatin

Description: Specified dose on specified day

Type: Drug

Module A Module B

Name: Paclitaxel

Description: Specified dose on specified day

Type: Drug

Module A Module B

Name: Pemetrexed

Description: Specified dose on specified day

Type: Drug

Module A Module B

Name: Cisplatin

Description: Specified dose on specified day

Type: Drug

Module A Module B


Primary Outcomes

Description: To compare the efficacy of nivolumab + ipilimumab combined with chemotherapy versus (vs)chemotherapy

Measure: Overall Survival (OS)

Time: Up to 31 months

Secondary Outcomes

Description: To compare the efficacy of nivolumab + ipilimumab combined with chemotherapy vs chemotherapy

Measure: Progression Free Survival (PFS)

Time: Up to 31 months

Description: To compare the efficacy of nivolumab + ipilimumab combined with chemotherapy vs chemotherapy

Measure: Overall Response Rate (ORR)

Time: Up to 31 months

Description: In participants with different PD-L1 levels

Measure: ORR

Time: Up to 31 months

Description: In participants with different PD-L1 levels

Measure: PFS

Time: Up to 31 months

Description: In participants with different PD-L1 levels

Measure: OS

Time: Up to 31 months

Measure: ORR, PFS, OS: In association with tumor mutation numbers

Time: Up to 31 months

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 L858R

Inclusion Criteria: - Participants with histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy - Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 - Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria - Participants must have PD-L1 IHC testing with results performed by a central laboratory during the screening period Exclusion Criteria: - Participants with known epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapy (including, but not limited to, deletions in exon 19 and exon 21 [L858R] substitution mutations) are excluded - Participants with known anaplastic lymphoma kinase (ALK) translocations which are sensitive to available targeted inhibitor therapy are excluded - Participants with untreated CNS metastases are excluded. --- L858R ---



HPO Nodes


HPO:
Neoplasm of the lung
Genes 61
REST GPC3 WT1 HPGD BRAF PIK3CA TP53 TRIM28 RB1 TRIP13 SLCO2A1 AKT1 CASP8 KRAS TSC1 POU6F2 EWSR1 PRKN LMNA NAB2 TERT TSC2 SLC22A18 BRCA2 PPP2R1B STAT6 STK11 MUC5B ERBB2 TSC2 MBTPS2 BAP1 TSC2 DICER1 PDGFRB PERP EGFR TSC1 DIS3L2 NOTCH3 KEAP1 DICER1 DICER1 WT1 TSC1 C11ORF95 IRF1 CYP2A6 WRN RELA WT1 PTEN SFTPC SFTPA2 ERCC6 TRPV3 TP53 H19 TRIM28 FASLG MAP3K8
Non-small cell lung carcinoma
Genes 3
TP53 TP53 BAP1